Filana Therapeutics Reports Simufilam Findings in TSC2-Deficient Cells
The company said findings published in Cells provide insight into simufilam’s effects on cellular stress responses and mitochondria.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Filana Therapeutics Reports Preclinical Simufilam Findings in TSC2-Deficient Cells
The research reports a 37% reduction in elevated ATF4, consistent with attenuation of the associated cellular stress response, and examines simufilam’s effects on cellular stress responses and mitochondrial function. Patient screening for a planned Phase 2a study is expected to begin.
Filana Therapeutics Reports Simufilam Findings Published in Cells
The company announced publication of preclinical findings for simufilam in TSC2-deficient cells.